|Last Update: 05/22/13 - 11:40 AM EDT|
|YTD Performance: 84.68%|
|Previous Close: $79.47|
|52 Week Range: $38.44 - $87.47|
|Oustanding Shares: 221,400,864|
|Market Cap: 17,131,998,856|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||7||7||10||10|
|Growth Rate (Year over Year)||-164.73%||n.a.%||-412.79%||33.29%|
The action just keeps chugging higher.
VRTX earnings estimates were increased to reflect faster penetration of CF, said UBS. Price target goes to $86.
I'm going to spend some time developing my watch list for next week.
VRTX's price target was increased to $100, said Deutsche Bank. F508del homozygous and other Kalydeco mutations are now expected to have a 100% success rate.
VRTX was initiated with a Hold rating, Canaccord Genuity said. Valuation call, based on a $55 price target.
VRTX earnings estimates were increased after speaking with physicians about the cystic fibrosis trial that is set to launch, said JPMorgan. Price target is now $86
VRTX was initiated with an Outperform rating, Robert Baird said. $53 price target. Cystic Fibrosis franchise can drive growth.
VRTX was downgraded to Neutral, Lazard Capital Markets said. Company is likely facing a transition year.
VRTX was downgraded from Outperform to Neutral, Credit Suisse said. $48 price target. Company will likely see lower Incivek sales.
VRTX was downgraded from Neutral to Sell, Goldman Sachs said. $43 price target. Have a more cautious outlook for the company's cystic fibrosis portfolio.